November 2018 (Supplement)

Feature

Special Article

The State of Clinical Pathways: Results From the Inaugural Journal of Clinical Pathways Benchmarking Survey

11/15/2019

Winston Wong, PharmD, Editor-in-Chief

Clinical pathways have become an integral part of oncology care. In use in oncology practices as early as the early 2000s, the prevalence of clinical pathways is expected to increase as the focus on value-based care...

...

11/15/2019

Journal of Clinical Pathways

News

Conference Coverage

Clinical Pathways for Ovarian Cancer

11/15/2019

JCP Editors

For ovarian cancer, in which treatment recurrence is a challenge and long-term maintenance therapy is often required, the clinical and financial implications of long-term treatment may differ from those of other...

For...

11/15/2019

Journal of Clinical Pathways

Conference Coverage

Highlighted Presentations from the 2018 Clinical Pathways Congress

11/15/2019

JCP Editors

Pros and Cons of Vendor- and Provider-Developed Pathways On Day 1 of the 2018 Clinical Pathways Congress, Bobby Daly, MD, MBA, Memorial Sloan Kettering Cancer Center (New York, NY), and Robin T. Zon, MD, FACP,...

Pros...

11/15/2019

Journal of Clinical Pathways

Insights

Interview

Pathways in an Evolving Treatment Landscape

11/15/2019

JCP Editors

Clinical pathways are prone to criticisms that they do not take patient diversity or the latest clinical advances into account, both of which can be addressed through comprehensive pathway design and updating...

...

11/15/2019

Journal of Clinical Pathways

Interview

Harnessing the Potential of Real-World Data to Support Clinical Pathways

11/15/2019

JCP Editors

Current clinical pathways are largely based on generalized measures such as evidence-based guidelines and consensus best practices. Yet electronic medical records (EMRs) contain a tremendous amount of data that, when...

...

11/15/2019

Journal of Clinical Pathways

Interview

Individualizing Treatment Within Clinical Pathways for Multiple Myeloma

11/15/2019

JCP Editors

Standardizing treatment options for relapsed/refractory multiple myeloma poses a challenge to clinical pathway decision-makers, due to the need to individualize treatment decisions for the patient’s specific...

...

11/15/2019

Journal of Clinical Pathways

Interview

An Oncology Pathways Pioneer Paves the Way for Pathways Across Medicine

11/15/2019

JCP Editors

In 2012, Dr Barbara L. McAneny was awarded a $19.76 million grant by the Center for Medicare & Medicaid Innovation to develop the Community Oncology Medical Home (COME HOME) model and implement that model in...

In...

11/15/2019

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

November 2018 (Supplement)

Feature

News

Insights

Current Issue

Special Reports

Subscribe

Volume 4

Specialties

Events

Year Round Education

HMP Global Products